Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA Q75E |
| Therapy | Alpelisib |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA Q75E | head and neck squamous cell carcinoma | predicted - sensitive | Alpelisib | Case Reports/Case Series | Actionable | In clinical case study, treatment with Piqray (alpelisib) resulted in a partial response with 73% tumor shrinkage in a patient with head and neck squamous cell carcinoma (HNSCC) harboring PIK3CA Q75E, and in a preclinical analysis, resulted in inhibition of proliferation and increased apoptosis in a HNSCC cell line expressing PIK3CA Q75E in culture (PMID: 34779417). | 34779417 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34779417) | Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. | Full reference... |